← The Wire
AMLXNasdaq
Amylyx Pharmaceuticals, Inc.
Pharmaceutical Preparations · DE · CIK 1658551
Develops novel therapies for endocrine conditions and neurodegenerative diseases, focusing on avexitide for hypoglycemia
$1.62B
Market cap
$18.70
Last close
+5.1%
1D
+14.9%
5D
2.4M
Volume
Price · last 39 sessions+13.6%
May 4L $12.74 · H $18.70Jun 29
100
Total filings
Jun 4, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteJun 4, 202610-Q10-QMay 7, 20268-KResults of OperationsMay 7, 2026DEFA14ADEFA14AApr 23, 2026DEF 14ADEF 14AApr 23, 20268-KReg FD DisclosureMar 24, 202610-K10-KMar 3, 20268-KResults of OperationsMar 3, 20268-KReg FD Disclosure · Company UpdateJan 8, 202610-Q10-QNov 6, 20258-KResults of OperationsNov 6, 20258-KMaterial AgreementSep 10, 2025424B5424B5Sep 10, 2025424B5424B5Sep 9, 20258-KCompany UpdateAug 27, 202510-Q10-QAug 7, 20258-KResults of OperationsAug 7, 20258-KShareholder VoteJun 5, 202510-Q10-QMay 8, 20258-KResults of OperationsMay 8, 2025DEFA14ADEFA14AApr 24, 2025DEF 14ADEF 14AApr 24, 202510-K10-KMar 4, 20258-KResults of OperationsMar 4, 20258-KMaterial AgreementJan 10, 2025424B5424B5 FINALJan 10, 2025424B5424B5Jan 10, 20258-KReg FD DisclosureDec 30, 202410-Q10-QNov 7, 20248-KResults of OperationsNov 7, 2024SC 13GSC 13GNov 4, 2024SC 13GSC 13GOct 25, 20248-KCompany UpdateOct 17, 2024SC 13GSC 13GAug 26, 202410-Q10-QAug 8, 20248-KResults of OperationsAug 8, 20248-KAcquisition / DispositionJul 10, 20248-KMaterial AgreementJun 21, 20248-KShareholder VoteJun 6, 202410-Q10-QMay 9, 20248-KResults of OperationsMay 9, 2024DEFA14ADEFA14AApr 24, 2024DEF 14ADEF 14AApr 24, 20248-KCompany UpdateApr 10, 20248-KExit / Disposal Costs · Reg FD DisclosureApr 4, 20248-KExecutive ChangeMar 14, 2024SC 13GSC 13GMar 11, 20248-KReg FD Disclosure · Company UpdateMar 8, 202410-K10-KFeb 22, 20248-KResults of OperationsFeb 22, 2024SC 13GSC 13GJan 29, 2024SC 13GAMYLYX PHARMACEUTICALS, INC.Dec 11, 20238-KReg FD DisclosureDec 7, 202310-Q10-QNov 9, 20238-KResults of OperationsNov 9, 20238-KCompany UpdateOct 13, 202310-Q10-QAug 10, 20238-KResults of OperationsAug 10, 20238-KCompany UpdateJul 26, 20238-KCompany UpdateJun 23, 2023SC 13GSC 13GJun 9, 20238-KShareholder VoteJun 9, 202310-Q10-QMay 11, 20238-KResults of OperationsMay 11, 2023DEFA14ADEFA14AApr 27, 2023DEF 14ADEF 14AApr 27, 20238-KExecutive ChangeMar 21, 202310-K10-KMar 13, 20238-KResults of OperationsMar 13, 20238-KReg FD DisclosureFeb 14, 2023SC 13GSC 13GFeb 13, 2023SC 13GSCHEDULE 13GFeb 9, 20238-KMaterial AgreementDec 6, 202210-Q10-QNov 10, 20228-KResults of OperationsNov 10, 20228-KExecutive ChangeNov 2, 2022424B4424B4Oct 7, 2022S-1S-1Oct 4, 20228-KCompany UpdateSep 30, 2022SC 13GSC 13GSep 21, 2022
Insider Activity
In the 90 days to Mar 2, 2026: 1 insider bought $101K · 5 sold $5.7M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 2, 2026 | Cohen Joshua BCo-Chief Executive Officer | Sell | 29,282 | $14.48 | $424K |
| Mar 2, 2026 | Klee Justin B.Co-Chief Executive Officer | Sell | 29,282 | $14.47 | $424K |
| Mar 2, 2026 | Frates James MChief Financial Officer | Sell | 7,909 | $14.52 | $115K |
| Mar 2, 2026 | Mazzariello GinaChief Legal Officer | Sell | 6,844 | $14.52 | $99K |
| Mar 2, 2026 | Bedrosian Camille LChief Medical Officer | Sell | 6,461 | $14.58 | $94K |
| Feb 23, 2026 | Mazzariello GinaChief Legal Officer | Sell | 3,419 | $14.14 | $48K |
| Feb 2, 2026 | Klee Justin B.Co-Chief Executive Officer | Sell | 15,500 | $14.69 | $228K |
| Feb 2, 2026 | Cohen Joshua BCo-Chief Executive Officer | Sell | 15,500 | $14.68 | $228K |
| Feb 2, 2026 | Frates James MChief Financial Officer | Sell | 3,557 | $14.65 | $52K |
| Feb 2, 2026 | Mazzariello GinaChief Legal Officer | Sell | 3,448 | $14.65 | $51K |
| Jan 16, 2026 | Klee Justin B.Co-Chief Executive Officer | Sell | 1,995 | $13.89 | $28K |
| Jan 16, 2026 | Cohen Joshua BCo-Chief Executive Officer | Sell | 1,974 | $13.83 | $27K |
| Jan 15, 2026 | Cohen Joshua BCo-Chief Executive Officer | Sell | 136,193 | $13.59 | $1.9M |
| Jan 15, 2026 | Klee Justin B.Co-Chief Executive Officer | Sell | 136,193 | $13.58 | $1.8M |
| Jan 6, 2026 | Klee Justin B.Co-Chief Executive Officer | Sell | 7,715 | $11.09 | $86K |
| Jan 6, 2026 | Cohen Joshua BCo-Chief Executive Officer | Sell | 7,715 | $11.09 | $86K |
| Jan 6, 2026 | Frates James MChief Financial Officer | Sell | 3,326 | $11.11 | $37K |
| Dec 23, 2025 | Firestone KarenDirector | Buy | 8,100 | $12.45 | $101K |
| Dec 1, 2025 | Bedrosian Camille LChief Medical Officer | Sell | 6,580 | $14.35 | $94K |
| Sep 30, 2025 | Klee Justin B.Co-Chief Executive Officer | Sell | 29,775 | $14.37 | $428K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance